Sandra Coetzee is a prominent inventor based in White Plains, NY (US). She has made significant contributions to the field of cancer treatment, particularly through her innovative work on antibodies targeting Mucin 16 (MUC16). With a total of 3 patents, her research focuses on developing novel therapeutic strategies for combating ovarian cancer.

Latest Patents

Coetzee's latest patents include groundbreaking inventions such as anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3. MUC16 is highly expressed in ovarian cancer, and its presence on cancer cells has been shown to protect these cells from the immune system. Her inventions provide novel full-length human IgG antibodies that specifically bind to human MUC16, as well as bispecific antibodies that activate T cells in the presence of MUC16-expressing tumors. These bispecific antigen-binding molecules are designed to inhibit the growth of tumors expressing MUC16 and are useful for treating various cancers, including ovarian cancer. Additionally, her anti-MUC16 antibody drug conjugates have demonstrated the ability to inhibit tumor growth in vivo.

Career Highlights

Sandra Coetzee is currently employed at Regeneron Pharmaceuticals, Inc., where she continues to advance her research in cancer therapeutics. Her work has been instrumental in developing innovative solutions that target MUC16, providing new avenues for treatment in oncology.

Collaborations

Coetzee collaborates with notable colleagues, including Lauric Haber and Eric L. Smith, to further enhance her research and its applications in the medical field.

Conclusion

Sandra Coetzee's contributions to cancer treatment through her innovative patents and research are paving the way for new therapeutic options for patients. Her work exemplifies the impact of targeted therapies in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.